Stock Screener App

無料 -

インストール

0.6105

4.04% 0.0237

Vistagen Therapeutics Inc (VTGN)

概要ニュース株価時系列オプションチェーン Financials ディスカッション予測株式分割

Vistagen Therapeutics Inc (VTGN) 最新ニュース

Vistagen Completes Last Patient Visit in PALISADE-4 Phase 3 Trial of Fasedienol Nasal Spray for Social Anxiety Disorder; Topline Results Expected Q2 2026 - Minichart

ex_558852.htm - SEC.gov

Vistagen (VTGN) completes PALISADE-4 randomized phase, eyes Q2 2026 data - Stock Titan

Vistagen (VTGN) Wraps Up Final Patient Visits in Phase 3 Anxiety Trial - GuruFocus

Vistagen completes enrollment in phase 3 anxiety trial By Investing.com - Investing.com Canada

Public-speaking challenge study ends; Vistagen data due this quarter - Stock Titan

Vistagen Therapeutics, Inc. (VTGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect - ACCESS Newswire

2026-05-05 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect | NDAQ:VTGN | Press Release - Stockhouse

Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) S - The National Law Review

Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Reach Out - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review

Vistagen (VTGN) wins FDA go-ahead to advance refisolone Phase 2 hot flash studies - Stock Titan

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop - Schubert Jonckheer & Kolbe

VistaGen appoints Nick Tressler as CFO - MSN

Vistagen Therapeutics Inc (MEX:VTGN) Competitors 2026 - GuruFocus

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to Reach Out - ACCESS Newswire

2026-04-26 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to Reach Out | NDAQ:VTGN | Press Release - Stockhouse

Who's Buying or Selling Vistagen Therapeutics Inc (MEX:VTGN) Stock Today? - GuruFocus

Vistagen Therapeutics Inc Stock Intrinsic Values | MEX:VTGN - GuruFocus

Vistagen Therapeutics Inc Stock Historical Valuations - GuruFocus

Vistagen Therapeutics Inc Stock Warning Signs - GuruFocus

Vistagen Therapeutics Inc (MEX:VTGN) Stock Price, Trades & News - GuruFocus

Q3 2026 Vistagen Therapeutics Inc Earnings Call Transcript - GuruFocus

Q3 2025 Vistagen Therapeutics Inc Earnings Call Transcript - GuruFocus

Q1 2026 Vistagen Therapeutics Inc Earnings Call Transcript - GuruFocus

Q2 2026 Vistagen Therapeutics Inc Earnings Call Transcript - GuruFocus

Vistagen Therapeutics Inc (MEX:VTGN) Stock Earnings Transcripts - GuruFocus

Vistagen Therapeutics (VTGN) price target decreased by 50.00% to 7.40 - MSN

Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Ther - The National Law Review

Vistagen advances PALISADE-4 trial with $61.8M in cash while refining placebo mitigation strategies - MSN

Vistagen Therapeutics (VTGN) Stock: Buy Decision Breakdown | Q1 2026: Earnings Beat EstimatesCertified Trade Ideas - Cổng thông tin điện tử tỉnh Tây Ninh

VistaGen Therapeutics, Inc. (VTGN) reports Q3 loss, lags revenue estimates - MSN

Breakthrough for Vistagen (VTGN) as FDA Approves Phase 2 Development - GuruFocus

Hot flash nasal spray moves ahead after FDA allows U.S. study - Stock Titan

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause - ChartMill

Vistagen Therapeutics, Inc. (VTGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors - WFXG

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm - TMX Newsfile

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update - ADVFN

Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeuti - The National Law Review

2026-04-16 | Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Shareholders to Inquire about Securities Investigation | NDAQ:VTGN | Press Release - Stockhouse

Vistagen Therapeutics Inc (MEX:VTGN) Stock Price & 30 Year Financial Data - GuruFocus

Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Connect - ACCESS Newswire

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Vistagen Therapeutics, Inc. Files Form 8-K with SEC – Company Information, Address, and Stock Details (April 2026) - Minichart

Vistagen Therapeutics grants stock options to executives and employees By Investing.com - Investing.com Australia

Vistagen Therapeutics grants stock options to executives and employees - Investing.com

VistaGen Therapeutics Grants Broad Employee Retention Stock Options - TipRanks

Vistagen awards stock options to CEO Shawn K. Singh and CFO Nick B. Tressler - TradingView

[8-K] Vistagen Therapeutics, Inc. Reports Material Event - Stock Titan

Institution Moves: Will Vistagen Therapeutics Inc outperform during market ralliesPortfolio Growth Summary & AI Forecasted Entry and Exit Points - baoquankhu1.vn

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Reach Out - ACCESS Newswire

2026-04-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Reach Out | NDAQ:VTGN | Press Release - Stockhouse

Trading Recap: What is the next catalyst for Vistagen Therapeutics IncInsider Selling & Low Volatility Stock Suggestions - baoquankhu1.vn

Vistagen Therapeutics Inc (MEX:VTGN) Stock HoldersInstitutional & Insider Ownership - GuruFocus

MRNA

$54.35

11.97%

INSM

$101.35

3.48%

RPRX

$50.79

1.18%

BNTX

$94.12

1.19%

RVMD

$141.81

0.49%

ONC

$312.12

1.54%

Yahooで開く | Google で開く | Finviz で開く | マーケットウォッチで開く | エドガーでオープン | ロイターで開く